NCT05375136View on ClinicalTrials.gov

A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

CompletedOBSERVATIONAL
Enrollment

135

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

November 7, 2023

Study Completion Date

November 7, 2023

Conditions
Endometrial NeoplasmsEndometriumCarcinomaRenal Cell Carcinoma
Interventions
OTHER

Non-interventional

No intervention will be administered.

Trial Locations (19)

Unknown

Eisai Site #04, Bundang

Eisai Site #02, Busan

Eisai Site #10, Busan

Eisai Site #17, Busan

Eisai Site #06, Daegu

Eisai Site #03, Ilsan

Eisai Site #05, Jeonju

Eisai Site #08, Seoul

Eisai Site #09, Seoul

Eisai Site #11, Seoul

Eisai Site #12, Seoul

Eisai Site #13, Seoul

Eisai Site #14, Seoul

Eisai Site #15, Seoul

Eisai Site #16, Seoul

Eisai Site #19, Seoul

Eisai Site #21, Seoul

Eisai Site #22, Seoul

Eisai Site #23, Seoul

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY